All the Therapeutic System Drugs
GIP and GLP-1 receptor agonist. Tirzepatide 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Multi-dose pre-filled pen. Sol. for SC inj. 4 X 2.5/5.0/7.5/10.0/12.5/15.0 mg
Starting dose is 2.5 mg once weekly. After 4 weeks, dose should be incr. to 5 mg once weekly. If needed, dose incr. can be made in 2.5 mg incr. after a min. of 4 weeks on the current dose. Recomm. maint. doses are 5 mg, 10 mg and 15 mg. Max. dose is 15 mg once weekly.
When added to existing metformin and/or sodium-glucose co-transporter 2 inhib. (SGLT2i) ther., current dose of metformin and/or SGLT2i can be continued. When added to existing ther. of a sulphonylurea and/or insulin, a reduct. in the dose of sulphonylurea or insulin may be considered to reduce risk of hypoglycaemia. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and insulin. A stepwise approach to insulin reduct. is recomm.
Tmt. of adults with insuffic. controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monother. when metformin is considered inappropriate due to intol. or contraindic. • in addition to other drugs for the tmt. of diabetes.
As an adjunct to a reduced-calorie diet and incr. phys. activity for weight management, including weight loss and weight maint., in adults with an initial Body Mass Index (BMI) of • ≥ 30 kg/m2 (obesity) or • ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, CV dis., prediabetes, or type 2 diabetes mellitus). For trial results with respect to obstructive sleep apnoea (OSA) in adults with obesity, see full prescript. info.
C/I: Hypersens.
CNS Stimulant. Phentermine (as resinate) 15 mg. CAPS (Sust. Act.):30 X 15. 1 cap. aft.breakf. accord. to instruct.
Tmt. of sev. obesity that has not respond. to appropriate diet- min.
BMI 30 is req.
Ind. as adjun. in med. monit. comprehen. regimen of wt. reduct. based on exercise, diet (cal. restrict.) and behav. mod.
C/I: Hypersens.
Pulmon. hypertens.
Exist. heart valve abnormalit./ heart murmur.
Mod.-sev. arter.hyperten.
Cerebrovasc. dis.
Sev. card. dis. includ. arrhythm.
Adv. arterioscleros.
Hyperthyroidis.
Agitated states/ history of psychiatr. ill. includ. anorexia nervosa and depres.
Glaucoma
History of drug/alcohol abuse or depend. Co-admin. with drug for weight loss.
Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml. PRE-FILL. PENS: 5. Init. 0.6 mg dly.
Dose should be incr. to 3.0 mg dly. in
increm. of 0.6 mg with at least one wk.
interv. to improve GI tolerabil. If escal.
to the next dose step is not tolerated
for two consec. wks., consider discont.
tmt. Dly. doses higher than 3.0 mg are
not recomm.
Adults: as adjunct to reduc. cal. diet and
incr. phys. act. for wt. managt. in pts. BMI
30 (obes.), or 27 to < 30 (overwt.) and at
least one comorbidity such as
dysglycaemia (pre-diabet. or type 2
diabet. Mellit.), hypertens., or
dyslipidaemia and who failed wt.
managt. intervent. Tmt. should be
discont. aft. 12 wks. on the 3 mg/day
dose if pts. have not lost at least 5% of
their initial BW. Adolescents (>12 years)
as an adjunct to a healthy nutr. and incr.
phys. act. for wt. managt. in pts. with
BMI=30. Tmt. should be discont. and
re-eval. if pts. have not lost at least 4% of
their BMI or BMI z score after 12 weeks on
the 3 mg/day or max. toler. dose. Re-eval.
should be perf. periodic.
C/I: Hypersens.
Glucagon-like peptide-1 (GLP-1) analogues. Semaglutide 0.25 mg, 0.5 mg , 1 mg, 1.7 mg, 2.4 mg. Pre-filled pen SC inj. 4X 0.25/0.5/1/1.7/2.4 mg
Adlts and adolesc: maint. dose of 2.4 mg once/w is reached by starting with a dose of 0.25 mg. To reduce likelihood of GI sympt., dose should be escalated over 16-week to the maint. dose of 2.4 mg once/w. See lit.
Adlts: as an adjunct to a red. calorie diet and incr. physical activity for weight managem., includ. weight loss and weight mainten., in adlts. with an initial BMI of
• ≥30 kg/m2 (obesity), or
• ≥27 kg/m2 to <30 kg/m2 (overweight) in presence of at least one weight-relat. comorbidity e.g. dysglycaemia (prediabetes or type 2 DM), hypertension, dyslipidaemia, obstructive sleep apnoea or CV dis.
Adolesc. (≥12 years): as an adjunct to a red. calorie diet and incr. physical activity for weight managem. in adolesc. with
• obesity* and
• body weight above 60 kg.
Tmt. to be discont. and re-eval. if adolesc. pts. have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or max. toler. dose. *Obesity (BMI ≥95th percentile) as def. on sex- and age-spec. BMI growth charts.
C/I: Hypersens
Lipase Inhibitor. Orlistat 120 mg. CAPS: 7, 21, 42, 84 x 120 mg.
Adults and child over 12 yrs:
1 cap. 3 x dly.
In conjunct. with mildly hypocaloric diet
for obese patients with a BMI greater or
equal to 30 kg/m2, or overweight patients
(BMI >28 kg/m2) with assoc. risk factors.
C/I: Hypersens., chron. malabsorpt.
syndr., cholestasis, lact.
